Press Releases

Date Title and Summary
Toggle Summary Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators
Latest research published in The Lancet Oncology : suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical CyberKnife platform
Toggle Summary Accuray to Host Meeting with Analysts and Investors at ASTRO on October 24, 2022
SUNNYVALE, Calif. , Oct. 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a key opinion leader (KOL) discussion with analysts and investors on Monday, October 24, 2022 , in conjunction with the American Society of Radiation Oncology (ASTRO)
Toggle Summary Accuray Announces First CyberKnife® Systems in Africa, Providing a New Option and Hope for Potentially Life-Saving Radiation Treatments for More Cancer Patients
World's Only Robotic Radiation Therapy Device Delivers Extremely Precise Treatments in Just 1 to 5 Out- Patient Sessions SUNNYVALE, Calif. , Sept. 30, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its
Toggle Summary Dr. Seth Blacksburg Joins Accuray as VP, Chief Medical Officer Americas Region
SUNNYVALE, Calif. , Sept. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Seth Blacksburg, M.D., MBA has joined the company as vice president, chief medical officer for the Americas ( North and South America ) region. Dr.
Toggle Summary Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster
Accuray Will Anchor Hub That Will Unite Companies From the MedTech , Pharma and Biosciences Sectors, Physicians and Scientists SUNNYVALE, Calif. , Sept. 7, 2022 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub , a
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results
8.5% FY22 revenue growth; Company issues guidance for FY23 SUNNYVALE, Calif. , Aug. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2022 ended June 30, 2022 .     Q4 Fiscal 2022 and Recent Operating Highlights Gross
Toggle Summary Accuray to Report Fiscal Year-End 2022 Financial Results on August 10, 2022
SUNNYVALE, Calif. , July 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2022, ended June 30, 2022 , after the market close on August 10, 2022 . Management will host a conference call to review the results at 1:30
Toggle Summary Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications
SUNNYVALE, Calif. , July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15 th   Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife®  platform
Toggle Summary Accuray Appoints Franco N. Palomba as VP, Chief Accounting Officer & Controller
SUNNYVALE, Calif. , June 15, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Franco N. Palomba has joined the company as vice president, chief accounting officer & controller. Mr. Palomba will be responsible for the controllership function, including the global
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , June 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Sandeep Chalke , the company's new senior vice president, chief commercial officer. As a material inducement to Mr.

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at